Skip Navigation LinksAbout-us

 The main points guiding our company development are summarized here:

  • Company founded to develop clinically useful assay at time of cancer diagnosis, useful for guiding treatment decisions
  • Company is dedicated to helping cancer patients achieve better outcomes with better quality of life and lower overall costs
  • Optical assay useful in predicting recurrence in low risk ER+ node negative breast cancer
  • Addresses problem of "overtreatment" in this low risk group
  • Assay is "Matrix" based so complementary to gene expression (cell based) assays
  • Clinical trials and other validation steps remain with algorithm development to include other parameters with predictive value
  • While discovery came by studying a population, application of the assay to individual cases with feedback on prediction will produce continuous improvement of the assay by design
  • Possible expansion to other solid tumors with evidence of application to colon cancer
  • Dedicated to the ultimate goal of cancer prevention by leveraging what we learn by following our patients prospectively and studying how they differ from cancer free individuals or long term survivors
  • We seek feedback from our potential customers to help guide us into becoming the company that will serve our customers' needs now and in the future